IMpower010: Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy

June 4-8, 2021; Online at

Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.

Format: Microsoft PowerPoint (.ppt)
File Size: 612 KB
Released: June 9, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset on the assessment of EGFR mutation and MET amplifications status in NSCLC, from Clinical Care Options (CCO)

Alexander Spira, MD, PhD, FACP Released: November 22, 2021

Downloadable slideset on the treatment of NSCLC harboring Exon 20 insertion mutations, from Clinical Care Options (CCO)

Enriqueta Felip, MD Released: November 22, 2021

Download this brief slideset on treatment options for advanced EGFR-mutated NSCLC that has progressed on first-line EGFR TKI therapy, from Clinical Care Options (CCO)

Helena A. Yu, MD Released: November 19, 2021

Download this brief slideset on resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Helena A. Yu, MD Released: November 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.